Patents by Inventor Pascal Andre Stein

Pascal Andre Stein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD19 antibodies with reduced immunogenicity
    Patent number: 11208496
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: December 28, 2021
    Assignee: Cancer Research Technology LTD.
    Inventors: Michael Super, Jonathan Davis, Pascal Andre Stein
  • ANTI-CD19 ANTIBODIES WITH REDUCED IMMUNOGENICITY
    Publication number: 20190241671
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Application
    Filed: September 10, 2018
    Publication date: August 8, 2019
    Inventors: Michael Super, Jonathan Davis, Pascal Andre Stein
  • Methods of use of anti-CD19 antibodies with reduced immunogenicity
    Patent number: 10072092
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: September 11, 2018
    Assignee: Merck Patent GmbH
    Inventors: Michael Super, Jonathan Davis, Pascal Andre Stein
  • METHODS OF USE OF ANTI-CD19 ANTIBODIES WITH REDUCED IMMUNOGENICITY
    Publication number: 20150322159
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Application
    Filed: February 12, 2015
    Publication date: November 12, 2015
    Inventors: Michael Super, Jonathan Davis, Pascal Andre Stein
  • Methods of treating cancer using interleukin-12p40 variants having improved stability
    Patent number: 9029330
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 12, 2015
    Assignee: Merck Patent GmbH
    Inventors: Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo, Pascal André Stein
  • Anti-CD19 antibodies with reduced immunogenicity
    Patent number: 8957195
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: February 17, 2015
    Assignee: Merck Patent GmbH
    Inventors: Michael Super, Jonathan Davis, Pascal André Stein
  • ANTI-CD19 ANTIBODIES WITH REDUCED IMMUNOGENICITY
    Publication number: 20140288288
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Application
    Filed: March 21, 2014
    Publication date: September 25, 2014
    Applicant: Merck Patent GmbH
    Inventors: Michael Super, Jonathan Davis, Pascal André Stein
  • Anti-CD19 antibodies with reduced immunogenicity
    Patent number: 8691952
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: April 8, 2014
    Assignee: Merck Patent GmbH
    Inventors: Michael Super, Jonathan Davis, Pascal André Stein
  • Interleukin-12 P40 Variants with Improved Stability
    Publication number: 20130034518
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Application
    Filed: May 23, 2012
    Publication date: February 7, 2013
    Applicant: Merck Patent GmbH
    Inventors: Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo, Pascal André Stein
  • INTERLEUKIN-12P40 VARIANTS WITH IMPROVED STABILITY
    Publication number: 20110097792
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Application
    Filed: December 7, 2010
    Publication date: April 28, 2011
    Applicant: Merck Patent GmbH
    Inventors: Gordon D. Webster, Suzanee P. McKenzie, Kin-Ming Lo, Pascal André Stein
  • DNA encoding IL-2 fusion proteins with modulated selectivity
    Patent number: 7888071
    Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: February 15, 2011
    Assignee: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Pascal Andre Stein, Kin-Ming Lo
  • Interleukin-12p40 variants with improved stability
    Patent number: 7872107
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: January 18, 2011
    Assignee: Merck Patent GmbH
    Inventors: Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo, Pascal André Stein